2018 Investor Information
Investor Materials
2017 Annual Report
2018 Proxy Statement
Vote Online
View a digital enhanced version of our Annual Report.
View a digital enhanced version of our Proxy Statement.
Your Vote is IMPORTANT! Vote online with any device. Vote by phone by dialing 866-356-9132.
* Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Annual Meeting
Date
Time
Location
October 1, 2018
10:30 AM CDT
507 Calles Street, Suite 112, Austin, TX 78702
About Us
Genprex is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
Meet The Board
Senior Management
J. Rodney Varner, JD
Chief Executive Officer & Executive Chairman
Julien L. Pham, MD, MPH
Chief Operating Officer
Ryan M. Confer, MS
Chief Financial Officer
Elizabeth Han, JD
Corporate Counsel
Board of Directors
David E. Friedman, JD
Board Member
Robert W. Pearson, MBA
Board Member
James E. Rothman, PhD
Strategic Advisor to the Board of Directors
Scientific & Medical Advisory Board
Jack A. Roth, MD, FACS
SAB Chairman
Pasi Antero Jänne, MD, PhD
SAB Board Member
Tony S.K. Mok, MD, FRCP
SAB Board Member
George Simon, MD, FACS
SAB Board Member
Powered by Donnelley Financial Solutions
Copyright © 2018 Mediant Communications Inc.
All Rights Reserved.
Investor Materials
2017 Annual Report
View a digital enhanced version of our Annual Report.
View Document
2018 Proxy Statement
View a digital enhanced version of our Proxy Statement.
View Document
Vote Online
Your Vote is IMPORTANT! Vote online with any device. Vote by phone by dialing 866-356-9132.
Vote Now
* Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Online
Date
Time
Location
Genprex is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
Learn More
J. Rodney Varner, JD
Chief Executive Officer & Executive Chairman
Julien L. Pham, MD, MPH
Chief Operating Officer
Ryan M. Confer, MS
Chief Financial Officer
Elizabeth Han, JD
Corporate Counsel
David E. Friedman, JD
Board Member
Robert W. Pearson, MBA
Board Member
James E. Rothman, PhD
Strategic Advisor to the Board of Directors
Jack A. Roth, MD, FACS
SAB Chairman
Pasi Antero Jänne, MD, PhD
SAB Board Member
Tony S.K. Mok, MD, FRCP
SAB Board Member
George Simon, MD, FACS
SAB Board Member